MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- AUROBINDO PHARMA - LUPIN
AUROBINDO PHARMA vs LUPIN - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
LUPIN 
Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
Current Valuations
| AUROBINDO PHARMA | LUPIN | AUROBINDO PHARMA/ LUPIN |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 13.7 | 40.5 | 33.8% | View Chart |
| P/BV | x | 2.8 | 2.5 | 112.8% | View Chart |
| Dividend Yield | % | 0.5 | 0.0 | - |
Financials
 AUROBINDO PHARMA  LUPIN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-18 |
LUPIN Mar-19 |
AUROBINDO PHARMA/ LUPIN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 809 | 986 | 82.0% | |
| Low | Rs | 504 | 720 | 70.0% | |
| Sales per share (Unadj.) | Rs | 281.1 | 369.5 | 76.1% | |
| Earnings per share (Unadj.) | Rs | 41.4 | 13.4 | 308.5% | |
| Cash flow per share (Unadj.) | Rs | 50.9 | 37.4 | 136.1% | |
| Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 199.4 | 303.7 | 65.6% | |
| Shares outstanding (eoy) | m | 585.88 | 452.49 | 129.5% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 2.3 | 2.3 | 101.2% | |
| Avg P/E ratio | x | 15.9 | 63.6 | 24.9% | |
| P/CF ratio (eoy) | x | 12.9 | 22.8 | 56.5% | |
| Price / Book Value ratio | x | 3.3 | 2.8 | 117.2% | |
| Dividend payout | % | 6.0 | 0 | - | |
| Avg Mkt Cap | Rs m | 384,630 | 386,064 | 99.6% | |
| No. of employees | `000 | 17.3 | 17.7 | 98.0% | |
| Total wages/salary | Rs m | 21,308 | 31,513 | 67.6% | |
| Avg. sales/employee | Rs Th | 9,500.7 | 9,453.8 | 100.5% | |
| Avg. wages/employee | Rs Th | 1,229.4 | 1,782.0 | 69.0% | |
| Avg. net profit/employee | Rs Th | 1,397.9 | 343.0 | 407.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 164,666 | 167,182 | 98.5% | |
| Other income | Rs m | 1,020 | 3,640 | 28.0% | |
| Total revenues | Rs m | 165,686 | 170,822 | 97.0% | |
| Gross profit | Rs m | 37,718 | 28,822 | 130.9% | |
| Depreciation | Rs m | 5,580 | 10,850 | 51.4% | |
| Interest | Rs m | 777 | 3,078 | 25.2% | |
| Profit before tax | Rs m | 32,380 | 18,534 | 174.7% | |
| Minority Interest | Rs m | 31 | -89 | -35.2% | |
| Prior Period Items | Rs m | 0 | 38 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | 0 | -3,400 | 0.0% | |
| Tax | Rs m | 8,183 | 9,017 | 90.7% | |
| Profit after tax | Rs m | 24,229 | 6,066 | 399.5% | |
| Gross profit margin | % | 22.9 | 17.2 | 132.9% | |
| Effective tax rate | % | 25.3 | 48.7 | 51.9% | |
| Net profit margin | % | 14.7 | 3.6 | 405.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 121,878 | 138,536 | 88.0% | |
| Current liabilities | Rs m | 86,806 | 61,299 | 141.6% | |
| Net working cap to sales | % | 21.3 | 46.2 | 46.1% | |
| Current ratio | x | 1.4 | 2.3 | 62.1% | |
| Inventory Days | Days | 130 | 84 | 155.0% | |
| Debtors Days | Days | 68 | 112 | 60.8% | |
| Net fixed assets | Rs m | 81,037 | 127,516 | 63.6% | |
| Share capital | Rs m | 586 | 905 | 64.7% | |
| "Free" reserves | Rs m | 116,218 | 136,517 | 85.1% | |
| Net worth | Rs m | 116,804 | 137,422 | 85.0% | |
| Long term debt | Rs m | 4,512 | 66,417 | 6.8% | |
| Total assets | Rs m | 211,052 | 279,494 | 75.5% | |
| Interest coverage | x | 42.7 | 7.0 | 607.7% | |
| Debt to equity ratio | x | 0 | 0.5 | 8.0% | |
| Sales to assets ratio | x | 0.8 | 0.6 | 130.4% | |
| Return on assets | % | 11.8 | 3.3 | 362.2% | |
| Return on equity | % | 20.7 | 4.4 | 470.0% | |
| Return on capital | % | 27.4 | 8.9 | 307.1% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 80,727 | 59,414 | 135.9% | |
| Fx outflow | Rs m | 34,700 | 22,282 | 155.7% | |
| Net fx | Rs m | 46,027 | 37,132 | 124.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 19,548 | 16,660 | 117.3% | |
| From Investments | Rs m | -19,570 | -32,825 | 59.6% | |
| From Financial Activity | Rs m | 8,642 | 7,441 | 116.1% | |
| Net Cashflow | Rs m | 8,922 | -8,724 | -102.3% | |
Share Holding
| Indian Promoters | % | 54.1 | 46.6 | 116.1% | |
| Foreign collaborators | % | 0.0 | 0.2 | - | |
| Indian inst/Mut Fund | % | 8.0 | 11.3 | 70.4% | |
| FIIs | % | 27.7 | 31.9 | 86.8% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.2 | 10.1 | 101.0% | |
| Shareholders | 69,601 | 98,259 | 70.8% | ||
| Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: PLETHICO PHARMA DIVIS LABORATORIES FULFORD INDIA ALKEM LABORATORIES AJANTA PHARMA
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Yes Bank's Road Ahead(Podcast)
The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.
Related Views on News
LUPIN 2018-19 Annual Report Analysis (Annual Result Update)
Jul 18, 2019 | Updated on Jul 18, 2019Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.
AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)
May 17, 2019 | Updated on May 17, 2019For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.
LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsMost Popular
These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)
Jul 9, 2019As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)
Jul 8, 2019A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...
Here's What to Do with Falling Small Cap Stocks(Profit Hunter)
Jul 10, 2019There are some great buying opportunities in the market right now - and the small cap space is your best bet.
Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)
Jul 10, 2019Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.
More|
| |
AUROBINDO PHARMA SHARE PRICE
Jul 19, 2019 (Close)
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA - PANACEA BIOTECH COMPARISON
COMPARE AUROBINDO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.